Sitagliptin Added-on to Insulin Study

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp. Identifier:
First received: November 1, 2006
Last updated: April 20, 2010
Last verified: April 2010

A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on insulin or insulin/metformin combination therapy.

Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: sitagliptin phosphate
Drug: Comparator : placebo (unspecified)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin (MK0431) to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy (Alone or In Combination With Metformin)

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Change From Baseline in A1C at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent.

Secondary Outcome Measures:
  • Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    Change from baseline at Week 24 is defined as Week 24 minus Week 0.

  • Change From Baseline in 2-hour Post-meal Glucose (PMG) at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    Change from baseline at Week 24 is defined as Week 24 minus Week 0.

  • Percent Change From Baseline in Index of Static Beta-Cell Sensitivity to Glucose at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    Static sensitivity is a measure of the effect of glucose on beta-cell secretion and is the ratio between the insulin secretion rate and glucose concentration above the threshold level at steady state. (See Breda and Cobelli, Annals of Biomedical Engineering 29, 692-700 (2001) for more details.)

  • Percent of Patients With A1C < 7.0% at Week 24 [ Time Frame: 24 Weeks ] [ Designated as safety issue: No ]
  • Percent of Patients With A1C < 6.5% at Week 24 [ Time Frame: Week 24 ] [ Designated as safety issue: Yes ]

Enrollment: 641
Study Start Date: December 2006
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: sitagliptin phosphate
sitagliptin 100 mg tablet qd for a 24-wk treatment period.
Other Names:
  • MK0431
  • Januvia™
Placebo Comparator: 2
Drug: Comparator : placebo (unspecified)
sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient has type 2 diabetes mellitus
  • Patient is poorly controlled while on insulin or insulin and metformin

Exclusion Criteria:

  • Patient has a history of type 1 diabetes mellitus or history of ketoacidosis
  • Patient is taking oral antidiabetic agents other than metformin during the past 3 months
  • Patient is currently on treatment with daily use of pre-prandial short-acting or rapid-acting insulin
  Contacts and Locations
Please refer to this study by its identifier: NCT00395343

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Additional Information:
No publications provided

Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp Identifier: NCT00395343     History of Changes
Other Study ID Numbers: 2006_532, MK0431-051
Study First Received: November 1, 2006
Results First Received: September 18, 2009
Last Updated: April 20, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on April 22, 2014